PIRAMAL ENTERPRISES LTD. - 500302 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation under Regulation 39(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 201522-02-2023
22-02-2023
PIRAMAL ENTERPRISES LTD. - 500302 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation of Schedule of Analyst/ Institutional Investor Meetings under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.16-02-2023
PIRAMAL ENTERPRISES LTD. - 500302 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation under Regulation 39(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 201515-02-2023
PIRAMAL ENTERPRISES LTD. - 500302 - Disclosure Under Regulation 30 Read With Regulation 31A Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 - Submission Of Application For Re-Classification From 'Promoter Group' Category To 'Public' Category Of Piramal Enterprises Limited
Disclosure under Regulation 30 read with Regulation 31A of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Submission of application for re-classification from 'Promoter Group' category to 'Public' category of Piramal Enterprises Limited15-02-2023
PIRAMAL ENTERPRISES LTD. - 500302 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 - Transcript of Conference Call with Investors/Analysts15-02-2023
Buy Piramal Enterprises of Rs 1300: Emkay Global Financial
Emkay Global Financial is bullish on Piramal Enterprises has recommended buy rating on the stock with a target price of Rs 1300 in its research report dated February 09, 2023.13-02-2023
Buy Piramal Enterprises; target of Rs 1150: Motilal Oswal
Motilal Oswal is bullish on Piramal Enterprises recommended buy rating on the stock with a target price of Rs 1150 in its research report dated February 09, 2023.11-02-2023
PIRAMAL ENTERPRISES LTD. - 500302 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation under Regulation 39(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 201509-02-2023
PIRAMAL ENTERPRISES LTD. - 500302 - Disclosure Under Regulation 30 Read With Regulation 31A Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015, As Amended - Re-Classification From 'Promoter Group' Category To 'Public' Category Of Piramal Enterprises Limited
Disclosure under Regulation 30 read with Regulation 31A of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended - Re-classification from 'Promoter Group' category to 'Public' category of Piramal Enterprises Limited09-02-2023
Piramal Pharma reports consolidated net loss of Rs 90 crore in Q3
Piramal Pharma on Thursday reported a net loss of Rs 90 crore on a consolidated basis for the third quarter ended December 31, 2022. The Mumbai-based company had reported a net profit of Rs 163 crore in the October-December quarter of last fiscal. Revenue from operations stood at Rs 1,716 crore for the third quarter, while the same was at Rs 1,539 crore in the year-ago period. The company said the third quarter results were not comparable to the same period last year as the NCLT in August 12, 2022 approved the composite scheme of demerger of the pharma business from Piramal Enterprises Ltd (PEL) into Piramal Pharma Ltd. The NCLT also approved amalgamation of Piramal Pharma's wholly-owned subsidiaries Hemmo Pharmaceuticals and Convergence Chemical into itself with an appointed date of April 1, 2022. Accordingly, the financial statements of Piramal Pharma have been prepared giving effect to the scheme from April 1, 2022. "Based on our recent increase in customer engagements and...09-02-2023